Using bisphosphonate to reduce tumor recurrence in bone tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study investigates the effectiveness of local bisphosphonate delivery as a surgical adjuvant to reduce the recurrence rate of giant cell tumors of bone. The approach involves using bisphosphonate-loaded PMMA bone cement during surgery to enhance outcomes compared to traditional aggressive surgical removal. The study will also assess secondary outcomes such as pain relief, functional improvement, and complications related to the surgery. The hypothesis is that this localized treatment will lead to better results than standard intralesional curettage alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary benign GCT of bone
* Lesion located in an extremity
* Lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal
* No previous systemic bisphosphonate or denosumab therapy

Exclusion Criteria:

* Recurrent GCT of bone
* Non-extremity location
* Lesion too extensive for intralesional treatment, either due to bone loss, joint invasion, or large soft tissue component
* Children and pregnancy
* Previous systemic bisphosphonate or denosumab therapy

Where it's running

• University of California - Los Angeles
  Los Angeles, California, United States Recruiting
• Indiana University
  Indianapolis, Indiana, United States Recruiting
• University of Iowa
  Iowa City, Iowa, United States Recruiting
• Johns Hopkins University Hospital
  Baltimore, Maryland, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting
• Boston Children's Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Allison Gruender, RN
• Email: allison.gruender@health.slu.edu
• Phone: 314-617-3406

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRACP-5b test to help diagnose and monitor giant cell tumor of bone

  This study tests whether a blood marker, TRACP-5b, can help diagnose and track giant cell tumor of bone in adults.

  Recruiting St. Anne's University Hospital Brno, Czech Republic · Brno · NCT07609277

• Indocyanine green fluorescence to find leftover giant cell tumor tissue during surgery

  We will try a dye called indocyanine green with near-infrared imaging during surgery to help surgeons spot any remaining giant cell tumor tissue in people having surgery for GCTB.

  Recruiting Phase 4 Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai · NCT07315828

• PROMIS questionnaires and smartphone mobility tracking after sarcoma surgery

  This project tests whether PROMIS questionnaires together with a new smartphone app can track recovery and mobility in adults undergoing surgery for sarcoma or giant cell tumor of bone.

  Recruiting at 2 sites University of Calgary · Phoenix, Arizona and 3 other locations · NCT07227961

• Using ICG imaging to improve surgery for giant cell tumors of bone

  This study is testing if a special imaging technique can help surgeons find and remove all parts of giant cell tumors in the bone to reduce the chances of them coming back after surgery.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06647901

• Using zoledronic acid-loaded bone cement to reduce recurrence of giant cell bone tumors after surgery

  This study tests if using a special bone cement with a drug can help prevent giant cell bone tumors from coming back after surgery, compared to regular bone cement.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT05595603

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.